Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737360 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of TAS-106 to Treat Head and Neck Cancer
A Phase 2 study, sponsored by Taiho Pharmaceutical Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00737360 is a Phase 2 study that was terminated before completion, run by Taiho Pharmaceutical Co.. The registered enrollment target is 27 participants.
The verdict
NCT00737360, a Phase 2 study, was terminated before completion, sponsored by Taiho Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
Interventions
- DRUG TAS-106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737360
The ClinicalTrials.gov registry entry for NCT00737360 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Pharmaceutical Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS-106 is the first listed.
NCT00737360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00737360 about?
NCT00737360 is a clinical study titled "Phase II Study of TAS-106 to Treat Head and Neck Cancer". The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
What is the current status of trial NCT00737360?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2008-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00737360?
The interventions under investigation include: TAS-106 (DRUG).
Who is sponsoring clinical trial NCT00737360?
This trial is sponsored by Taiho Pharmaceutical Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.